We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BiondVax to Present Phase IIa Results at 2011 BIO International Convention
Product News

BiondVax to Present Phase IIa Results at 2011 BIO International Convention

BiondVax to Present Phase IIa Results at 2011 BIO International Convention
Product News

BiondVax to Present Phase IIa Results at 2011 BIO International Convention


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BiondVax to Present Phase IIa Results at 2011 BIO International Convention"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BiondVax Pharmaceuticals Ltd. has announced that the company's Chief Scientific Officer, Dr. Tamar Ben-Yedidia, will present the results of the Company's Phase IIa clinical trial at the 2011 BIO International Convention:

2011 BIO International Convention
27 - 30 June 2011, in Washington, D.C., USA
Title: Clinical progress towards a universal influenza vaccine
http://convention.bio.org/

The Phase IIa clinical trial was a randomized, double-blind, placebo-controlled, multi-center, safety and immunogenicity study in 200 healthy volunteers, aged 18-49, being conducted at two clinical research centers in Israel.

In February 2011, BiondVax announced positive interim safety results from the trial. These results showed that no severe adverse events were found in any of the participants, further reinforcing the positive safety profile of the Multimeric-001 vaccine found in the Company’s Phase I/II trials.

BiondVax is currently in the final stages of collecting and analyzing the data regarding the immunogenicity of the vaccine, and will announce the final results of the trial prior to the presentation at BIO at the end of June.

Advertisement